Mitomycin Medac (Mitomycin)

Mitomycin is used in oncology for the treatment of several solid tumours, primarily through intravenous or intravesical administration.

• Bladder cancer (non‑muscle invasive): reduces tumour recurrence after transurethral resection when given intravesically.
• Gastric cancer (advanced): provides cytotoxic activity as part of combination chemotherapy regimens.
• Pancreatic cancer (metastatic): contributes to tumour control when used in multi‑agent protocols.

• Mitomycin exerts its antineoplastic effect by undergoing enzymatic reduction within hypoxic tumour cells, forming a highly reactive alkylating species. This species creates covalent cross‑links between DNA strands, preventing DNA unwinding and replication. The resulting inhibition of DNA synthesis triggers apoptosis and cell death, particularly in rapidly proliferating malignant cells. The drug preferentially accumulates in cells with low oxygen tension, enhancing its selectivity for solid tumours.

Mitomycin may cause a range of adverse reactions, varying from mild to severe, that require monitoring during therapy.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported.
• Myelosuppression: decreased white blood cells, platelets, and red cells.
• Fatigue: general tiredness and reduced stamina.
• Mucositis: inflammation of the mouth and gastrointestinal lining.
• Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects

• Hemorrhagic cystitis: bladder bleeding due to local toxicity.
• Severe bone marrow failure: aplastic anemia or pancytopenia.
• Pulmonary fibrosis: progressive scarring of lung tissue.
• Renal toxicity: impaired kidney function.
• Allergic reactions: rash, pruritus, or anaphylaxis.

Before initiating Mitomycin therapy, clinicians should evaluate patient-specific factors and implement safety measures to minimize risks.

• Renal function: assess baseline creatinine and adjust dosing in impairment.
• Hepatic function: monitor liver enzymes as the drug is metabolized hepatically.
• Bone marrow status: obtain complete blood count prior to each cycle to detect myelosuppression.
• Pregnancy and lactation: avoid use due to unknown fetal risk; discontinue if pregnancy occurs.
• Concurrent nephrotoxic or ototoxic agents: use with caution to prevent additive toxicity.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mitomycin can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid)

• Cisplatin: combined use markedly increases nephrotoxicity and myelosuppression.
• Radiation therapy: concurrent administration heightens risk of severe tissue damage.
• Anticoagulants: may exacerbate hemorrhagic cystitis and bleeding tendencies.

Moderate Interactions (Monitor Closely)

• Azathioprine or other immunosuppressants: enhanced bone marrow suppression.
• High‑dose folinic acid: may reduce antitumor activity.
• Nephrotoxic antibiotics (e.g., aminoglycosides): increase risk of renal impairment.